In pa­tients with symp­tom­at­ic mi­cro­scop­ic coli­tis, the AGA re­com­mends treat­ment with bu­des­o­nide over no treat­ment for the in­duc­tion of clin­i­cal re­mis­sion.

Evidence for Recommendation 1

In pa­tients with symp­tom­at­ic mi­cro­scop­ic coli­tis in whom bu­des­o­nide ther­a­py is not fea­si­ble, the AGA sug­gests treat­ment with me­sala­mine over no treat­ment for the in­duc­tion of clin­i­cal re­mis­sion.

In pa­tients with symp­tom­at­ic mi­cro­scop­ic coli­tis in whom bu­des­o­nide ther­a­py is not fea­si­ble, the AGA sug­gests treat­ment with pred­nis­o­lone (or pred­ni­sone) over no treat­ment for the in­duc­tion of clin­i­cal re­mis­sion.

In patients with symptomatic microscopic colitis, the AGA suggests against treatment with Boswellia serrata over no treatment for the induction of clinical remission.

For pa­tients with re­cur­rence of symp­toms fol­low­ing dis­con­tin­u­a­tion of in­duc­tion ther­a­py for mi­cro­scop­ic coli­tis, the AGA re­com­mends bu­des­o­nide for main­te­nance of clin­i­cal re­mis­sion.